Introduction {#s1}
============

Apolipoprotein E (ApoE) ε4 genotype is the strongest and most prevalent risk factor for late-onset Alzheimer's disease (AD) ([@bib9]; [@bib50]). ApoE binds to and modulates the function of ApoE receptors, a family of LDL receptor-related proteins (LRPs) and postsynaptic signal transducers that regulate glutamatergic neurotransmission in the CNS ([@bib60]; [@bib3]; [@bib27]) and the formation of the neuromuscular synapse in the periphery ([@bib59]; [@bib66]; [@bib36]).

Mutations in the amyloid precursor protein (APP) cause early-onset AD ([@bib20]). APP and its pathogenic cleavage product, β-amyloid, physically and functionally interact with ApoE receptors on multiple levels ([@bib37]), by regulating the trafficking and processing of APP ([@bib56]; [@bib47]; [@bib2]; [@bib30]; [@bib31]; [@bib43]), mediating amyloid clearance ([@bib2]; [@bib10]) and by preventing amyloid-induced synaptic suppression at the synapse ([@bib14]). Intriguingly, APP is also expressed at the neuromuscular junction ([@bib1]) and APP family members are required for normal formation and function of the neuromuscular junction ([@bib53]; [@bib57], [@bib58]), although the underlying mechanisms remain unclear. APP family members have also been shown to contribute to synaptic function in the CNS ([@bib61]).

Although APP occupies such a central role in the pathogenesis of AD, its physiological functions and how they relate to the disease process on the molecular level remains poorly understood. ApoE ε4 genotype strongly predisposes to an earlier age of AD onset, increasing the relative risk in individuals \>65 years of age by approximately 10-fold ([@bib9]; [@bib50]). APP and ApoE interact with LRPs, thus suggesting a role of ApoE receptors in AD pathogenesis ([@bib26]). Besides serving as cargo receptors that can mediate the endocytosis of ApoE containing lipoprotein particles, ApoE receptors have also been shown to function as signal transducers that regulate essential signaling pathways during development and in the adult organism, where they control glutamate receptor function, synaptic plasticity, memory and learning (reviewed in [@bib27]). Examples include brain development (LRP8, VLDLR), vascular development and maintenance (LRP1), kidney and neuromuscular junction formation (LRP4), and others (reviewed in [@bib12]).

The NMJ is a specialized peripheral cholinergic synapse ([@bib25]; [@bib49]; [@bib63]). Impaired cholinergic neurotransmission has been implicated in AD and this forms the conceptual basis for the therapeutic use of cholinesterase inhibitors. Both APP and LRP4 are required for normal NMJ formation, and the LRP4 ligand agrin is abundantly expressed in the CNS ([@bib6]; [@bib45]; [@bib52]). Furthermore, MuSK localizes to excitatory synapses ([@bib38]) and has been shown to mediate cholinergic responses, synaptic plasticity and memory formation ([@bib18]), while agrin was found to regulate synaptogenesis ([@bib44]) and prevent synapse loss in the cortex ([@bib38]). These intriguing similarities between MuSK, agrin and ApoE receptors in synaptic maintenance and function prompted us to explore the NMJ as a model system on which potentially novel functional interactions between APP and ApoE receptors could be investigated. We found that LRP4 and APP physically bind to each other and that APP can also bind agrin. Ligation of LRP4 by immobilized APP can activate MuSK in the absence of neural agrin. Simultaneous and stoichiometric interaction of the three proteins favors the formation of a hetero-oligomeric complex, which may serve to focus the formation of the NMJ at the surface of the myotube.

Results {#s2}
=======

NMJ formation in mice lacking membrane-anchored LRP4 {#s2-1}
----------------------------------------------------

A common mechanism by which ApoE receptors directly transduce or indirectly modulate extracellular signals involves the interaction of adaptor proteins with their intracellular domain (ICD) ([@bib54], [@bib55]; [@bib22]). We therefore generated three mutant *Lrp4* alleles in mice to test which domains of LRP4 are required for NMJ development. Consistent with the previous report that mice with point mutations in *Lrp4* die at birth ([@bib59]), mice carrying a novel *Lrp4* null allele, which we generated by deleting exon 1 of murine *Lrp4* ([Figure 1A](#fig1){ref-type="fig"}), also die perinatally from a complete failure to form NMJs ([Figure 2A](#fig2){ref-type="fig"}). By contrast, mice carrying an *Lrp4* allele encoding a truncated receptor consisting of only the extracellular domain (ECD), but lacking the transmembrane segment and intracellular domain (ICD), are viable ([@bib32]), indicating that at least partially functional NMJs must form and that thus neither membrane anchoring of the LRP4 ECD nor its ICD is absolutely required for the formation of the NMJ ([@bib13]; [@bib21]). To further test this hypothesis, we first set out to determine to what extent membrane anchoring of the LRP4 receptor is required for NMJ formation. We examined NMJs of *Lrp4*^ECD/ECD^ mice, in which we introduced a stop codon immediately before the transmembrane segment. This results in the expression of LRP4 with the extracellular domain, but without the transmembrane domain or the intracellular domain ([Figure 1B](#fig1){ref-type="fig"}) ([@bib32]).10.7554/eLife.00220.003Figure 1.Targeting vectors.Diagrammatic representation of gene replacement strategies used to generate *Lrp4*^−/−^ (null allele, **A**), *Lrp4*^ECD/ECD^ (hypomorphic allele without membrane anchor, **B**), and *Lrp4*^ΔICD/ΔICD^ (**C**) mice. Exons encoding the LRP4 ECD are depicted in blue and indicated by brackets. The exon encoding the transmembrane segment is shown in red, cytoplasmic domain encoding exons in green. To generate the *Lrp4* null allele, the transcription start site and exon 1 were replaced with a neo cassette (**A**). To generate the *Lrp4* ΔICD allele, a cDNA cassette encoding the transmembrane segment of LRP4 (TM, red) followed by a Myc epitope and bovine growth hormone 3′UTR was introduced into the targeting vector described by [@bib32]. This results in the normal expression of the LRP4 ECD and transmembrane segment, but complete replacement of the ICD with a Myc tag (**C**). The generation of the LRP4 ECD allele has been described in [@bib32] (**B**).**DOI:** [http://dx.doi.org/10.7554/eLife.00220.003](10.7554/eLife.00220.003)10.7554/eLife.00220.004Figure 2.NMJ development in *Lrp4* mutant mice.(**A**) Embryonic diaphragm muscles (E16.5) from wild-type (top row), *Lrp4*^--/--^ (middle row) and *Lrp4*^ECD/ECD^ mice (bottom row) were double-labeled with anti-syntaxin antibodies (green) for decorating innervating fibers and with α-bungarotoxin (red) to detect AChRs. In both wild-type and *Lrp4*^ECD/ECD^ muscles, AChRs are clustered along the central region juxtaposed to nerve terminals. By contrast, AChR clusters are completely absent and NMJs fail to form in *Lrp4*^--/--^ muscles. (**B**) Triangularis sterni muscles at postnatal day 12 were stained for nerves in green (anti-NF150 and anti-Syt2 antibodies) and AChRs in red (α-bungarotoxin). In both wild-type (left column) and *Lrp4*^ΔICD/ΔICD^ mice (middle column), neuromuscular synapses were distributed within a narrow band near the nerve trunk. By contrast, neuromuscular synapses in *Lrp4*^ECD/ECD^ mice (right column) were distributed across a broader region of the muscle, as prolonged nerve branches extended from the nerve trunk. Furthermore, AChR clusters are markedly smaller in the *Lrp4*^ECD/ECD^ muscle, compared with the wild-type or *Lrp4*^ΔICD/ΔICD^ muscle (bottom row: high-power views of AChR clusters). Scale bars, **A**: 300 µm; **B**: 200 µm (top three rows) and 50 µm (bottom row).**DOI:** [http://dx.doi.org/10.7554/eLife.00220.004](10.7554/eLife.00220.004)

One of the hallmarks of NMJ formation is that presynaptic nerve terminals progressively accumulate synaptic vesicles in juxtaposition with AChR clusters that accumulate on the postsynaptic membrane ([@bib48]; [@bib63]). We therefore double-labeled embryonic diaphragm muscles (E16.5) with anti-syntaxin antibodies and α-bungarotoxin to detect presynaptic nerve terminals and postsynaptic AChRs, respectively. In contrast to the complete absence of pre- and postsynaptic differentiation in *Lrp4* null mice ([Figure 2A](#fig2){ref-type="fig"}, middle row), neuromuscular synapses were present in the E16.5 *Lrp4*^ECD/ECD^ embryos. Presynaptic terminals were properly juxtaposed to postsynaptic AChR clusters ([Figure 2A](#fig2){ref-type="fig"}, bottom row), which aligned along the central region of the muscle, although the density of the AChR appeared reduced. These results indicate an initial formation of the NMJs in E16.5 *Lrp4*^ECD/ECD^ embryos.

Membrane anchoring, but not the intracellular domain (ICD) of LRP4 is required for postnatal growth and maturation of the NMJ {#s2-2}
-----------------------------------------------------------------------------------------------------------------------------

Next, we tested whether membrane anchoring of LRP4 further enhances the function of the ECD or whether the ICD is required to achieve full functionality. To do this, we took advantage of a mouse line carrying a novel *Lrp4* knockin allele in which the ICD had been replaced with a Myc-tag (*Lrp4*^ΔICD/ΔICD^, [Figure 1C](#fig1){ref-type="fig"}). Triangularis sterni muscle from these mice was isolated at P12 and NMJs were stained with anti-syntaxin antibodies and α-bungarotoxin. NMJs developed normally in the *Lrp4*^ΔICD/ΔICD^ mice ([Figure 2B](#fig2){ref-type="fig"}, middle column), with synapse size indistinguishable from wild type (left column). These results are also consistent with the lack of an obvious neuromuscular phenotype in a strain of cattle affected by Mulefoot disease, where a naturally occurring splice site mutation in *Lrp4* results in truncation of the protein and a nearly complete loss of the cytoplasmic domain ([@bib33]).

By contrast, the impaired development of NMJs in *Lrp4*^ECD/ECD^ mice continues during the postnatal period. AChR clusters were distributed more diffusely in P12, the triangularis sterni muscle of *Lrp4*^ECD/ECD^ mice, compared with wild-type or *Lrp4*^ΔICD/ΔICD^ mice ([Figure 2B](#fig2){ref-type="fig"}). In adult muscles, the NMJ from *Lrp4*^ECD/ECD^ mice remained noticeably smaller than that from age-matched wild-type mice. As shown in [Figure 3A](#fig3){ref-type="fig"}, in the triangularis sterni muscle from 3-month old *Lrp4*^ECD/ECD^ mice, the pre-synaptic nerve terminal and post-synaptic AChR clusters remained markedly smaller compared with wild type. By contrast, the NMJ in *Lrp4*^ΔICD/ΔICD^ mice developed to similar size as wild type ([Figure 3B](#fig3){ref-type="fig"}). Thus, although the NMJ was established in *Lrp4*^ECD/ECD^ embryos, it remained considerably smaller (compared with age-matched wild-type control) at postnatal and adult stages, indicating that LRP4 membrane anchoring is required for the growth and maturation of the NMJ. Intriguingly, the ultrastructure of the nerve terminal and post-synaptic membrane appeared largely normal---with abundant presynaptic vesicles and elaborate junctional folds ([Figure 3C](#fig3){ref-type="fig"}). We examined 55 nerve terminal profiles from 18 *Lrp4*^ECD/ECD^ NMJs and 74 profiles from 23 control NMJs and found no statistical difference between control and *Lrp4*^ECD/ECD^.10.7554/eLife.00220.005Figure 3.Reduced NMJ size in *Lrp4*^*ECD/ECD*^ mice.(**A**) Triangularis sterni (TS) muscles from wild type (WT) and 3-month-old *Lrp4*^ECD/ECD^ mice double-labeled with anti-syntaxin antibodies (green, nerve) and α-bungarotoxin (red, AChRs). The NMJ in the *Lrp4*^ECD/ECD^ muscle is markedly smaller than in the wild-type muscle. (**B**) Size comparison of neuromuscular synapse areas in TS muscles in 3-month-old wild-type, *Lrp4*^ECD/ECD^ and *Lrp4*^ΔICD/ΔICD^ mice. **(C**) Electron micrographs of NMJs from lumbrical muscles in 2-month old *Lrp4*^WT/ECD^ and littermate *Lrp4*^ECD/ECD^ mice. Nerve terminals containing numerous synaptic vesicles and mitochondria are embedded in the muscle surface and junctional folds are apparent in both genotypes. Scale bars, 1 μm. 55 nerve terminal profiles from 18 *Lrp4*^ECD/ECD^ NMJs and 74 profiles from 23 control NMJs were analyzed. Representative images are shown. Arrow indicates junctional fold. SV: synaptic vesicle; mito: mitochondria.**DOI:** [http://dx.doi.org/10.7554/eLife.00220.005](10.7554/eLife.00220.005)

Furthermore, despite a significant reduction in sizes, only a minor fraction (2%) of synapses was innervated by more than one axon in *Lrp4*^ECD/ECD^ NMJs at P12, as was the case in the wild type. Moreover, the γ-ε switch also occurred normally in the *Lrp4*^ECD/ECD^ mutant. By P16 γ-AChR subunit expression was no longer detectable on the protein or mRNA level in wild-type, *Lrp4*^wt/ECD^ or *Lrp4*^ECD/ECD^ muscle (data not shown). Therefore, deleting the transmembrane and intracellular domains of LRP4 had no impact on the process of synapse elimination and AChR subunit switch (from the embryonic γ to the adult ε form) at the NMJ.

These findings indicate that the LRP4 intracellular domain harbors no essential elements for relaying the molecular signals that govern NMJ formation, but that membrane anchoring of LRP4 is required for maintaining the level of signal strength necessary for postnatal growth and maturation of the neuromuscular synapses. On the other hand, secretion of the extracellular domain of LRP4 into the pericellular space is apparently sufficient to initiate clustering of AChRs and thus manifestation of immature NMJs that can then be maintained at the prevailing reduced signal strength. This is consistent with the findings in conditional *Musk* knockout mice ([@bib29]), which showed NMJ disassembly in postnatal muscle upon conditional MuSK inactivation, indicating the requirement for continuous MuSK activity in postnatal muscle.

Genetic interaction of *App* and *Lrp4* during NMJ development {#s2-3}
--------------------------------------------------------------

This low level signaling may in part be mediated by the interaction of LRP4 ECD with MuSK ([@bib66]; [@bib36]). However, several ApoE receptors have also been reported to interact directly or indirectly with APP ([@bib37]; [@bib56]; [@bib47]; [@bib2]; [@bib30]; [@bib31]; [@bib43]), and APP itself has been shown to participate in NMJ development ([@bib57]). Taken together, these findings suggested that LRP4 might act synergistically with APP to regulate NMJ development and maintenance. To test this hypothesis, we bred *Lrp4*^ECD/ECD^ mice with *App*^−/−^ mice to generate *Lrp4*^ECD/ECD^ and *App* double mutant mice. We found that postnatal survival of compound mutant mice was markedly reduced when three wild-type *Lrp4* and *App* alleles were deleted (e.g., *Lrp4*^+/ECD^*App*^--/--^ or *Lrp4*^ECD/ECD^*App*^+/--^) and that the survival of double mutant mice (*Lrp4*^ECD/ECD^*App*^--/--^) was significantly reduced (p\<0.01) ([Table 1](#tbl1){ref-type="table"}). Because of this accelerated loss of the compound double mutant animals before weaning, we analyzed the NMJ in E18.5 embryos rather than in adults, as normal Mendelian distribution was observed at E18.5 in these mice (data not shown). As has been reported earlier ([@bib57]), normal size of AChR clusters was observed at the NMJ of *App*^--/--^ embryos ([Figure 4A,B](#fig4){ref-type="fig"}, d--f, compared to wild type in subpanels a--c, [Figure 4C](#fig4){ref-type="fig"}). In *Lrp4*^ECD/ECD^ embryos, AChR cluster size was similar to wild-type muscles, but AChR density was decreased ([Figure 4C](#fig4){ref-type="fig"}). However, in *Lrp4*^ECD/ECD^*App*^--/--^ double mutant embryos, both the density and the size of AChR clusters were significantly reduced compared to wild-type, *App*^--/--^ or *Lrp4*^ECD/ECD^ single mutant mice ([Figure 4C](#fig4){ref-type="fig"}). Furthermore, nerve terminal sprouting was markedly increased in the double mutant mice ([Figure 4A,B,j--l](#fig4){ref-type="fig"}). The significant reduction in the synaptic area of individual double mutant NMJs compared to wild type and *Lrp4*^ECD/ECD^ is also apparent in the three-dimensional rendition of individual synapses ([Figure 4A,m--o](#fig4){ref-type="fig"}). Similar findings were obtained in *Lrp4*^ECD/ECD^ mice lacking the amyloid precursor protein family member APLP2 ([Figure 5](#fig5){ref-type="fig"}), which cooperates with APP in the development of the NMJ ([@bib57]).10.7554/eLife.00220.006Table 1.Postnatal survival of *Lrp4*^ECD/ECD^;*App*^−/−^ double mutant mice**DOI:** [http://dx.doi.org/10.7554/eLife.00220.006](10.7554/eLife.00220.006)GenotypeExpectedObservedChi-square test*Lrp4*^+/ECD^;*App*^+/−^6374n.s.*Lrp4*^+/ECD^;*App*^−/−^4445n.s.*Lrp4*^ECD/ECD^;*App*^+/−^4949n.s.*Lrp4*^ECD/ECD^;*App*^−/−^3815[\*](#tblfn1){ref-type="table-fn"}[^3][^4][^5]10.7554/eLife.00220.007Figure 4.Impairment of pre-and post-synaptic development in *Lrp4*^*ECD/ECD*^;*App*^*--*/--^ double mutant mice.(**A**) (**a**--**l**) Wholemount staining of TS muscles (E18.5) double-labeled with anti-neurofilament antibodies and anti-Syt2 antibodies (nerve, **a**, **d**, **g**, **j**) and α-bungarotoxin (AChR, **b**, **e**, **h**, **k**). Merged images are shown in panels **c**, **f**, **i** and **l**. The inset in each panel shows a high-power view of the image. AChR clusters were markedly reduced both in number and size in *Lrp4*^ECD/ECD^;*App*^−/−^ mice (**j**--**l**), compared to wild type (**a**--**c**), *App*^−/−^ (**d**--**f**) or *Lrp4*^ECD/ECD^ (**g**--**i**). Furthermore, numerous terminal sprouts (arrowheads in the inset of **j** and **l**) were seen in *Lrp4*^ECD/ECD^;*App*^−/−^ mutant mice, whereas the nerve terminals in the wild type (arrowhead in **a**) juxtaposed with postsynaptic AChR clusters. **m**--**o**: 3D reconstruction of confocal images of the NMJs in wholemount diaphragm muscles in wild type (**m**), *Lrp4*^ECD/ECD^ (**n**) and *Lrp4*^ECD/ECD^;*App*^−/−^ (**o**) illustrate the reduced size of the NMJ in (**o**). Scale bars: **a**--**l**: 100 µm; inset: 20 µm. (**B**) Wholemount staining of diaphragm muscles (E18.5) double-labeled with anti-neurofilament antibodies and anti-Syt2 antibodies (nerve, **a**, **d**, **g**, **j**) and α-bungarotoxin (AChR, **b**, **e**, **h**, **k**). Low-power views of the left dorsal region of the diaphragm muscles. Scale bar, 400 µm. The number of AChR clusters was notably reduced in *Lrp4*^ECD/ECD^ mice, compared to wild-type and *App*^−/−^ mice. However both the size and number of AChR clusters were markedly reduced in *Lrp4*^ECD/ECD^;*App*^−/−^ mice, compared to wild-type, *App*^−/−^ and *Lrp4*^ECD/ECD^ mice. (**C**) Quantitative analysis of AChR clusters size and numbers. The number of AChR clusters at the ventral regions of right hemi-diaphragm muscles (E18.5), normalized by muscle area (upper panel). Average size of AChR clusters (lower panel). The numbers of AChR clusters analyzed are: 144 wild type, 132 *App*^−/−^, 131 *Lrp4*^ECD/ECD^ and 96 *Lrp4*^ECD/ECD^;*App*^−/−^ (N = 3 mice for each genotype). Data are shown as average ± S.E.M. Pairwise multiple comparisons were carried out using Tukey's test and the statistical differences determined by one-way analysis of variance (ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.00220.007](10.7554/eLife.00220.007)10.7554/eLife.00220.008Figure 5.Impairment of pre-and post-synaptic development in *Lrp4*^*ECD/ECD*^;*Aplp2*^*--/--*^ double mutant mice.Wholemount staining of triangularis sterni muscles (E18.5) double-labeled with anti-neurofilament antibodies and anti-Syt2 antibodies (nerve, **a**, **d**, **g**, **j**) and α-bungarotoxin (AChR, **b**, **e**, **h**, **k**). Merged images are shown in panels **c**, **f**, **i** and **l**. The inset in each panel shows a high-power view of the image. The nerve terminals and AChR clusters were markedly reduced (both in number and size) in *Lrp4*^ECD/ECD^;*Aplp2*^−/−^ mice (**j**--**l**), compared to wild type (**a**--**c**), *Aplp2*^−/−^ (**d**--**f**) or *Lrp4*^ECD/ECD^ (**g**--**i**). Arrowhead in the inset of **l** indicates a nerve terminal sprout. Scale bars: **a**--**l**: 100 µm; inset: 20 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.00220.008](10.7554/eLife.00220.008)

Biochemical interaction of APP and LRP4 extracellular domains {#s2-4}
-------------------------------------------------------------

These results indicate that *Lrp4* and the *App* family members, *App* and *Aplp2*, interact genetically and functionally in the formation of NMJs and that loss of *App* or *Aplp2* greatly enhances the synaptic defect in *Lrp4*^ECD/ECD^ mice. To test, whether APP and LRP4 interact directly, analogous to the interactions of APP with LRP1 ([@bib37]) and Apoer2 ([@bib30]), we performed a binding analysis using recombinant APP and LRP4 fusion proteins. The LRP4 ligand-binding domain (LBD) was fused to maltose-binding protein (MBP) and the APP ECD was fused to the constant Fc region of human IgG. [Figure 6A](#fig6){ref-type="fig"} shows that specific, ectodomain-dependent interaction of both fusion proteins does indeed occur. To further corroborate these findings, we performed a cellular aggregation analysis in which we transiently co-transfected 293 cells with GFP and full length APP, or RFP and full length LRP4 plasmids, respectively. Equal numbers of red, green or both types of fluorescent cells were mixed, and the number of aggregates was scored ([Figure 6B](#fig6){ref-type="fig"}). Significantly more and larger aggregates formed in the presence of APP and LRP4 than in control experiments in which cells were only transfected with GFP, RFP, APP+GFP, and LRP4+RFP, respectively ([Figure 6C](#fig6){ref-type="fig"}, note approximately equal numbers of APP and LRP4 expressing cells in the aggregates in [Figure 6B](#fig6){ref-type="fig"}). Although homophilic interaction of APP has been reported ([@bib51]), no increase in the number of large clusters was detected in wells containing only APP or LRP4 expressing cells, indicating a higher affinity of APP for LRP4 than for itself.10.7554/eLife.00220.009Figure 6.APP interacts with LRP4.(**A**) APP-Fc-bead conjugates or blank beads were incubated with 100 ng purified MBP or MBP-LRP4LBD for 4 hr at 4°C prior to immunoprecipitation with anti-MBP followed by immunoblotting with anti-hFc antibody (lane 3--7). Lanes 1 and 2 show MBP (control protein) and MBP-LRP4LBD, respectively. (**B**) GFP- and RFP-expressing HEK293T or APP/GFP- and LRP4/RFP-expressing HEK293T cells were mixed in suspension and incubated for 30 min at 37°C before capturing cell aggregates under a fluorescent microscope. (**C**) The number of aggregates bigger than 3000 µm^2^ from twelve randomly selected images was determined. A significantly (p\<0.0001) increased number of aggregates were present only when APP and LRP4 expressing cells were mixed. (**D**) APP and LRP4 protein levels in the transfected HEK293T cells.**DOI:** [http://dx.doi.org/10.7554/eLife.00220.009](10.7554/eLife.00220.009)

APP and agrin cooperate to promote AChR clustering {#s2-5}
--------------------------------------------------

The direct interaction between the LRP4 LBD and APP ectodomain suggested that pre- and/or post-synaptically expressed APP itself might be capable of engaging LRP4, thereby inducing MuSK phosphorylation and thus triggering AChR clustering on its own or cooperatively with the neural form of agrin (henceforth referred to as agrin unless stated otherwise). To test for this possibility, we exposed isolated myotubes to recombinant dimeric APP-Fc or RAP-Fc, an ER chaperone that binds the extracellular domains of ApoE receptors, that is LDL receptor family members ([@bib17]) including LRP4 ([@bib46]), with high affinity and thereby prevents the binding of most cognate ligands to this class of receptors ([@bib28]). To facilitate MuSK ligation, the Fc fusion proteins were immobilized on protein A beads and beads were incubated with isolated myotubes. [Figure 7A](#fig7){ref-type="fig"} shows that APP-Fc beads, but not RAP-Fc beads, significantly increased AChR clustering in the absence of exogenous neuronal agrin. When the same experiment was performed in the presence of a low concentration of agrin (0.1 ng/ml), again only APP-Fc, but not RAP-Fc, significantly increased AChR clustering. These results indicate that APP and agrin function synergistically through LRP4 to stimulate AChR clustering and NMJ formation. Interestingly, soluble APP-Fc not bound to beads was also able to promote AChR clustering, suggesting that focal clustering of APP on opposing beads is not required, but that the interaction of APP, either in a dimeric (APP-Fc) or monomeric (APP-FLAG) form ([Figure 7B](#fig7){ref-type="fig"}), with the myotube surface is sufficient to induce initial clustering. The soluble LRP4-ligand binding domain (MBP-LRP4) was also capable of inducing clustering, alone or together with the APP-ectodomain ([Figure 7B](#fig7){ref-type="fig"}). Moreover, the failure of RAP-Fc to induce AChR clustering suggests that LRP4 dimerization alone is not sufficient, but that possibly the formation of an extracellular scaffold ([@bib5]) through interactions with other surface proteins, which can be mediated by APP and LRP4 ECD, is required.10.7554/eLife.00220.010Figure 7.APP activates MuSK and promotes AChR clustering.(**A**) C2C12 myotubes were incubated with the indicated beads preloaded with APP-Fc or RAP-Fc, respectively, in the absence or presence of 0.1 ng/ml agrin for 24 hr prior to labeling AChRs. The number of average AChR clusters per 200 µm myotube was counted from 50 randomly captured images and normalized to control levels. (**B**) Monomeric and divalent recombinant APP fusion proteins and MBP-LRP4, alone or in combination with APP fusion proteins, are equally effective in inducing AChR clustering. C2C12 myotubes were incubated with 1 µg/ml of soluble monovalent APP (APP-Flag), divalent APP (APP-Fc), or MBP-LRP4, alone or in combination with APP fusion proteins, for 24 hr prior to labeling AChRs. (**C**) Myotubes were incubated for 30 min at 37°C with the indicated relative molar concentrations of proteins prior to immunoblotting for total MuSK and tyrosine phosphorylated MuSK (pTyr-MuSK). 0.1 nM Agrin = 9 ng/ml, 0.1 nM APP-Fc = 13 ng/ml, 10 nM RAP-Fc = 720 ng/ml. (**D**) Relative amounts of pTyr-MuSK were quantified from three independent experiments. At all APP concentrations MuSK phosphorylation was significantly increased for agrin alone (0.1 nM APP, p=0.0003; 1 nM APP, p=0.0002; 10 nM APP, p=0.0031). (**E**) APP-induced AChR clustering requires LRP4 and MuSK. Primary myotubes cultured from wild-type (WT), *Lrp4*−/−, and *Musk*−/− mouse embryos (E18.5) were incubated in the absence (control) or presence of APP-Fc for 24 hr prior to labeling AChRs. Statistical analysis by Student's *t*-test. Scale bars, 30 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.00220.010](10.7554/eLife.00220.010)

APP induces MuSK phosphorylation independent of agrin {#s2-6}
-----------------------------------------------------

These findings were further corroborated by determining the effect of APP-Fc on MuSK phosphorylation in the absence or presence of different concentrations of agrin ([Figure 7C](#fig7){ref-type="fig"}). At low concentrations (0.1 nM) agrin alone increased MuSK phosphorylation by 5.4-fold over baseline. RAP-Fc was used as a control and had no effect, whereas APP-Fc alone also dose-dependently increased MuSK phosphorylation, although not as effectively as agrin (2.4, 3.2 and 4.3-fold over baseline at 1×, 10× or 100× molar concentrations, respectively, compared to 0.1 nM agrin alone). However, at low (0.1 nM) to intermediate (1 nM) concentrations APP-Fc significantly increased MuSK phosphorylation by agrin further ([Figure 7C,D](#fig7){ref-type="fig"}). At higher concentration (10 nM), APP-Fc became less effective, suggesting that APP and agrin cooperatively enhance MuSK phosphorylation within a narrow physiological concentration range.

As was expected from the analysis of mice genetically deficient for LRP4 or MuSK, respectively, recombinant APP-Fc failed to induce any detectable AChR clustering in LRP4 or MuSK deficient myotubes ([Figure 7E](#fig7){ref-type="fig"}), indicating that APP can enhance but not bypass the essential activities of LRP4 and MuSK in NMJ formation.

APP, LRP4, and agrin interact cooperatively {#s2-7}
-------------------------------------------

These observations suggested that APP itself might interact directly with agrin and that this interaction might serve to cooperatively enhance a hetero-oligomeric interaction between APP, LRP4 and agrin to maximize MuSK phosphorylation and thereby focus AChR clustering to the narrow patch of the membrane destined to harbor the emerging NMJ. To test this hypothesis, we determined whether APP, LRP4 and MuSK form a stable complex in muscle in vivo. Wild-type embryonic muscle proteins were precipitated with antibodies against LRP4, as well as Apoer2 and LRP1, two other LDL receptor family members that are expressed in muscle and are known to interact with APP. Remarkably, only LRP4 co-precipitated with APP and with MuSK, indicating that these three proteins are already present in muscle in a preformed stable complex ([Figure 8A](#fig8){ref-type="fig"}).10.7554/eLife.00220.011Figure 8.Interactions between agrin, APP and LRP4.(**A**) APP, LRP4 and MuSK form a stable complex in muscle in vivo. Proteins were extracted from wild-type embryo (E14.5) muscles and incubated with polyclonal anti-LRP4, anti-Apoer2, or anti-LRP1 antibodies overnight at 4°C followed by adsorption to Protein A Dynabeads. Supernatants were efficiently immunodepleted of LRP4, Apoer2 and LRP1 with the respective antibodies. APP and MuSK coprecipitate with LRP4, but not with the other LRP members Apoer2 and LRP1, indicating the presence of a physiological complex consisting of LRP4, APP and MuSK in muscle in vivo. (**B**) Control (non-transfected), LRP4-Fc, APP-Fc, or RAP-Fc containing HEK293T supernatants were adsorbed with Protein A sepharose beads. Conjugated beads were incubated with 1 µg neural agrin in a final volume of 1 ml for 4 hr at 4°C, followed by immunoblotting for bound Fc proteins and agrin. (**C**) APP-Fc-bead conjugates or blank beads were incubated with purified 100 ng of MBP-LRP4LBD and 0--1000 ng of neural agrin for 4 hr at 4°C. The precipitate was analyzed by immunoblotting with anti-MBP, anti-agrin, and anti-Fc antibodies to detect cooperative protein interactions among LRP4, APP, and agrin. (**D**) Control (lanes 1--3), agrin Z0 (lanes 4--6), agrin Z8 (lanes 7--9), or agrin Z19 (lanes 10--12) containing culture supernatants were incubated overnight at 4°C in the absence (lanes 1, 4, 7, 10) or presence of RAP-Fc (lanes 2, 5, 8, 11) or APP-Fc (lanes 3, 6, 9, 12) prior to adsorption to Protein A coupled Dynabeads and magnetic isolation. Bound agrin isoforms and Fc proteins were determined by immunoblotting with anti-Myc and anti-Fc antibodies.**DOI:** [http://dx.doi.org/10.7554/eLife.00220.011](10.7554/eLife.00220.011)

Next, we performed a qualitative interaction assay to determine whether agrin can interact independently with the APP ectodomain. To this end, LRP4-Fc, APP-Fc and RAP-Fc fusion proteins were prepared and incubated with a fixed concentration of agrin (100 ng/ml). LRP4-Fc efficiently bound agrin at much lower concentrations than was required to achieve comparable binding to APP-Fc ([Figure 8B](#fig8){ref-type="fig"}), while RAP-Fc did not interact with agrin at all. To test whether the ability of APP to bind agrin, albeit at much lower affinity than LPR4, translates into a cooperative enhancement of the interaction of APP with LRP4, we incubated a fixed concentration of APP-Fc (100 ng/ml) with a fixed amount of LRP4-MBP (100 ng/ml) in the absence or presence of increasing amounts of agrin. As shown in [Figure 8C](#fig8){ref-type="fig"}, agrin dose-dependently enhanced the interaction of LRP4 with APP at 10 ng/ml (1.3-fold) up to an optimal concentration ratio of 30 ng/ml (threefold higher binding than in the absence of agrin). Higher concentrations of agrin potently inhibited the interaction of LRP4 with APP to 60% of baseline at 100 ng/ml and 10% at 300 ng/ml, respectively. At 1000 ng/ml, which equates to an approximately 15-fold molar excess of agrin, LRP4 binding to APP was completely abolished. This finding suggests that LRP4 and APP may bind agrin through different epitopes. Independent binding of different agrin molecules to LRP4 and APP may thus induce steric inhibition, which prevents the formation of the favored hetero-oligomeric complex consisting of LRP4, APP, agrin and, on the surface of the myotube, MuSK.

Agrin occurs in multiple splice forms ([@bib71]; [@bib15], [@bib16]; [@bib6]) of which the Z0 form is expressed by non-neural tissues such as muscle, while Z8 and Z19 are neural-specific. To test whether APP selectively interacts with specific agrin isoforms, we performed pull-down analysis with APP-Fc. [Figure 8D](#fig8){ref-type="fig"} shows that all three agrin isoforms (Z0, Z8 and Z19) interact with APP, although Z0 binding to APP appears less robust than Z8 or Z19 does.

AChR prepatterning is maintained in *App*/*Aplp2* double mutant muscle {#s2-8}
----------------------------------------------------------------------

To determine whether muscle prepatterning is affected in *App*^--/--^;*Aplp2*^--/--^ double mutant mice, we analyzed E14.5 muscles. Consistent with previous report that AChRs clusters are prepatterned in E14.5 muscle ([@bib40], [@bib69]), AChR clusters were aligned along the central region of E14.5 wild-type muscle, and the majority of AChR clusters were near, but not directly apposed by presynaptic nerve terminals ([Figure 9](#fig9){ref-type="fig"}). Similarly, prepatterned AChRs were distributed along the central region of *App*^--/--^;*Aplp2*^--/--^ muscle, although individual AChR clusters appear less robust compared with those in the wild-type, *App*^--/--^ or *Aplp2*^--/--^ muscles. These results demonstrate that pre-patterned AChR clustering is maintained in the absence of APP and APLP2.10.7554/eLife.00220.012Figure 9.AChR prepatterning in the absence of APP and APLP2.Wholemounts of embryonic diaphragm muscles (E14.5) from wild type (**a**--**c**), *App*^--/--^ (**d**--**f**), *Aplp2*^--/--^ (**g**--**i**) and *App*^--/--^;*Aplp2*^--/--^ (**j**--**l**) embryos were double-labeled with α-bungarotoxin (red) and anti-syntaxin antibodies (green). In wild-type and all mutant embryos, AChR clusters were confined to the central regions of diaphragm muscles indicating AChR prepatterning is independent of APP and APLP2. However, individual AChR clusters appear less robust in *App*^--/--^;*Aplp2*^--/--^ muscle compared with those in the wild-type, *App*^--/--^ or *Aplp2*^--/--^ muscles. Scale bar: 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.00220.012](10.7554/eLife.00220.012)

Localization of LRP4 in the absence of APP and APLP2 {#s2-9}
----------------------------------------------------

We next asked if removing membrane anchoring of LRP4 (as in *Lrp4*^ECD/ECD^ mice) or deleting *App* and *Aplp2* (as in *App*/*Aplp2* double mutant mice) might affect LRP4 protein distribution in muscles. We generated anti-LRP4 antibodies against the extracellular domain of LRP4 and performed immunofluorescence staining on embryonic muscles. As expected, no LRP4 labeling was detected in *Lrp4*^--/--^ muscle ([Figure 10A,k](#fig10){ref-type="fig"}; [Figure 10C,b](#fig10){ref-type="fig"}). By contrast, specific LRP4 staining was clearly visible at the NMJ in E18.5 WT muscle ([Figure 10A,h](#fig10){ref-type="fig"}), although the staining was markedly weaker at earlier developmental stages (E14.5 \[[Figure 10A,b](#fig10){ref-type="fig"}\] and E16.5 \[[Figure 10A,e](#fig10){ref-type="fig"}\]). Similarly, APP was also localized at the NMJ in E18.5 WT muscle ([Figure 10B](#fig10){ref-type="fig"}). In *Lrp4*^ECD/ECD^ muscle ([Figure 10C,e](#fig10){ref-type="fig"}), we detected LRP4 staining at the NMJ, but at reduced levels compared with WT muscle ([Figure 10D](#fig10){ref-type="fig"}). Strikingly, LRP4 staining was also reduced in *App*^--/--^;*Aplp2*^--/--^ double mutant muscle ([Figure 10C,h](#fig10){ref-type="fig"}), compared to WT muscle ([Figure 10D](#fig10){ref-type="fig"}). In adult muscle (hindlimb, 10-week-old), higher LRP4 protein ([Figure 10E](#fig10){ref-type="fig"}) and mRNA ([Figure 10F](#fig10){ref-type="fig"}) expression were detected in *Lrp4*^ECD/ECD^ compared to WT muscle. Taken together, these data indicate a decreased LRP4 level at the NMJ in *Lrp4*^ECD/ECD^ and *App*^--/--^;*Aplp2*^--/--^ embryonic muscles.10.7554/eLife.00220.013Figure 10.LRP4 localization in *Lrp4*^*ECD/ECD*^ and *App*^*--/--*^;*Aplp2*^*--/--*^ mutant mice.(**A**) Cross sections of hindlimb muscle from E14.5 (**a**--**c**), E16.5 (**d**--**f**) and E18.5 (**g**--**i**) wild type (WT) and E18.5 *Lrp4*^--/--^ (**j**--**l**) mice were double-labeled with anti-LRP4 antibodies (green) and Texas-Red conjugated α-bungarotoxin (red), which marks the site of the NMJ (arrowhead in **a**, **d**, **g**). LRP4 staining appears at low level in E14.5 WT and E16.5 WT muscle (compared with *Lrp4*^--/--^ muscle), and become highly concentrated at the NMJ in E18.5 WT muscle (arrowhead in **h**). Scale bar in **A**: 20 µm. (**B**) Localization of APP at the NMJ. Wholemount diaphragm muscle from E18.5 WT mice was double-labeled with anti-APP antibodies (**b**) and Texas-Red conjugated α-bungarotoxin (**a**). APP (arrowhead in **b**) is localized at the NMJ (arrowhead in **a**), as shown in the merged image in **c**. Scale bar in **B**: 10 µm. (**C**) Cross sections of hindlimb muscles from *Lrp4*^--/--^ (**a**--**c**), *Lrp4*^ECD/ECD^ (**d**--**f**) and *App*^--/--^;*Aplp2*^--/--^ (**g**--**i**) mice (E18.5) were double-labeled with anti-LRP4 antibodies (green) and α-bungarotoxin (red). LRP4 was detected at the NMJ in *Lrp4*^ECD/ECD^ (arrowhead in **e**) and *App*^--/--^;*Aplp2*^--/--^ (arrowhead in **h**), but not in *Lrp4*^--/--^ muscle (**b**). LRP4 expression appeared diffused in *Lrp4*^ECD/ECD^ and in *App*^--/--^;*Aplp2*^--/--^ muscles compared with age-matched WT muscle (see **A**). Scale bar in **C**: 30 μm. (**D**) Quantification of relative fluorescence intensity for LRP4 immunostaining on hindlimb myofibers from WT, *Lrp4*^ECD/ECD^ and *App*^--/--^;*Aplp2*^--/--^ mice (E18.5). Gray value of LRP4 staining at the NMJ (defined as signal) and within the sarcoplasm (defined as background) of the same myofiber was separately measured using ImageJ. The ratio of signal to background was then calculated for each individual myofiber. The bar graph shows significant (p\<0.05) decreases in LRP4 staining in *Lrp4*^ECD/ECD^ (1.38 ± 0.05, n = 23 myofibers) and *App*^−/−^;*Aplp2*^−/−^ (1.33 ± 0.05, n = 22 myofibers), compared with WT muscle (1.78 ± 0.18, n = 19 myofibers). (**E**) Anti-LRP4 and beta-actin (loading control) immunoblot shows increased level of LRP4 protein expression in *Lrp4*^ECD/ECD^ and *Lrp4*^WT/ECD^ muscle, compared with WT muscle (from the hindlimb muscles of 10-week-old mice). (**F**) *Lrp4* mRNA expression in hindlimb muscles (10-week-old mice) was determined by quantitative PCR. Levels of *Lrp4* mRNA were normalized to cyclophilin mRNA levels. Results are shown as average ± SD of triplicates.**DOI:** [http://dx.doi.org/10.7554/eLife.00220.013](10.7554/eLife.00220.013)

Discussion {#s3}
==========

Our results have revealed previously unrecognized interactions at the NMJ between LRP4 and APP on the one hand and APP and agrin on the other. Genetic epistasis experiments show that LRP4 and APP functionally interact to regulate NMJ development and maintenance. APP may accomplish this through several independent mechanisms: first, APP interacts directly with LRP4 and thereby is capable of activating MuSK (at a low level and independent of agrin) by ligating and clustering LRP4. Second, APP can also directly bind to agrin, albeit at lower affinity than LRP4. However, agrin cooperatively increases the stoichiometric interaction of APP with LRP4, which may serve to focus MuSK activation and thereby prevent aberrant AChR clustering. Third, APP and its homologues, which are expressed pre- and post-synaptically ([@bib57]), bind homomerically and heteromerically to each other ([@bib51]), thereby generating or strengthening attachment sites for nerve terminals ([@bib53]; [@bib1]; [@bib51]; [@bib57]). By interacting simultaneously with LRP4 and agrin, APP and potentially APP-like proteins such as APLP2, which also participates in NMJ formation ([@bib57]), would further serve to recruit all components necessary for AChR clustering into an area of maximal density, thereby ensuring that AChR clustering is restricted in vivo to the site of nerve contact. A rendition of this model is shown in [Figure 11A](#fig11){ref-type="fig"}.10.7554/eLife.00220.014Figure 11.Hypothetical model of the interactions of APP/APLP2, LRP4, agrin and MuSK during NMJ formation.(**A**) Our genetic, biochemical and functional results suggest that APP interacts with LRP4 and agrin to regulate NMJ formation. APP--LRP4 interaction in the absence of agrin may be able to activate MuSK signaling ([Figure 7C](#fig7){ref-type="fig"}) at low levels to promote AChR clustering on the muscle fiber membrane, raising the possibility that nerve and muscle-derived APP and APLP2 homo- or heterodimerization may be able to cooperatively promote AChR clustering in the absence of agrin, which provides a potential mechanism for the earlier observation that initial AChR clustering is independent of agrin ([@bib40]; [@bib64]). Neural agrin (red) enhances the APP--LRP4 interaction and strongly activates MuSK ([Figures 7C and 8C](#fig7 fig8){ref-type="fig"}), which is consistent with the role of agrin in the stabilization and maintenance of NMJs. Cooperative binding of APP and agrin to LRP4 ([Figure 8C](#fig8){ref-type="fig"}) would further strengthen LRP4--APP interaction on muscles, promoting synaptic differentiation and postnatal maintenance of NMJs (solid line with arrow in muscle fiber cytoplasm). By contrast, muscle agrin (gray), which cannot activate MuSK, would compete with decreasing concentrations of diffusible neural agrin at increasing distance from the NMJ and thus keep AChR clustering outside the nerve contact site suppressed. (**B**) Loss of the LRP4 membrane anchor results in a secreted ectodomain that remains partially functional through bivalent interactions with MuSK ([@bib66]; [@bib36]) and APP, resulting in reduced signaling (dashed line with arrow) and thus a hypomorphic NMJ developmental defect compatible with embryonic NMJ formation, but impaired postnatal maturation and maintenance of the NMJ.**DOI:** [http://dx.doi.org/10.7554/eLife.00220.014](10.7554/eLife.00220.014)

We have shown that LRP4 ECD is sufficient to initiate NMJ formation at embryonic stages but not sufficient for postnatal maturation, which requires a progressive increase of MuSK activation. The secreted LRP4 ectodomain that is encoded by our LRP4 ECD allele is presumably retained at the cell surface by simultaneous interactions with APP (possibly also APLPs), MuSK and agrin, but at levels that are insufficient to sustain the signal strength required for postnatal expansion of the synapse ([Figure 11B](#fig11){ref-type="fig"}). Also supporting this model is the finding that initial AChR clustering is independent of neuronal agrin ([@bib40]; [@bib64]) and that rudimentary NMJs form in agrin-deficient mice ([@bib19]), which suggested the existence of a second nerve derived organizing signal. By contrast, NMJs completely fail to form in *Musk* ([@bib11]) and *Lrp4* ([@bib59]) knockout mice, indicating an absolute requirement for MuSK and LRP4. Our finding that APP-Fc, but not RAP-Fc, can interact with LRP4 and induce MuSK phosphorylation at low level independent of agrin is consistent with both observations. Interestingly, however, and in contrast to our results with LRP4, the intracellular domain of APP appears to be required for normal NMJ development ([@bib39]). This suggests a role of these highly conserved C-terminal sequences in either signaling with APP serving as a co-receptor in the MuSK signaling complex, or a role in regulating the trafficking of all or part of the components of this complex.

It is conceivable that promotion of AChR clustering by homo- or heteromeric interaction of APP with itself or APLP2, and through inclusion of LRP4 and MuSK, requires an additional protein that interacts with the APP cytoplasmic domain, and that this requirement resembles the need for the interaction of rapsyn with the AChR and MuSK ([@bib5]). In their study, Bromann and colleagues further showed that immobilized, but not soluble, agrin is able to aggregate MuSK and promote AChR clustering independent of MuSK's kinase activity, suggesting that MuSK scaffolding plays an important role in AChR clustering. Our findings show that APP is independently capable of promoting AChR clustering, and that it further enhances clustering in the presence of agrin. Moreover, agrin potentiates the interaction of APP with LRP4. Thus, it is conceivable that APP cooperates with agrin and LRP4 to establish such an extracellular scaffold to promote MuSK aggregation and AChR clustering. AChR clustering can also be mediated by a variety of agrin independent mechanisms, including treatment with neuraminidase and VVA lectin ([@bib42]; [@bib23],[@bib24]) and by defucosylation of muscle agrin, which unmask its ability to induce MuSK phosphorylation ([@bib35]).

In addition, we have also obtained further evidence showing functional interaction of LRP4, APP and agrin during NMJ formation. We have analyzed mutant mice that lack the *App* family member *Aplp2* on the background of homozygous LRP4 ECD (*Lrp4*^ECD/ECD^;*Aplp2*^--/--^). Like *App*, *Aplp2* is also required for normal NMJ formation, and mice lacking both *App* family members exhibit aberrant apposition of presynaptic marker proteins with postsynaptic acetylcholine receptors and excessive nerve terminal sprouting and a reduced number of synaptic vesicles at presynaptic terminals ([@bib57]). This phenotype is consistent with the role of *App* family members in mediating trans-synaptic adhesion functions ([@bib58]) through homo- and hetero-oligomeric interactions ([@bib51]). Loss of both APP and APLP2, but not of either protein alone, might critically reduce this trans-synaptic interaction ([Figure 11](#fig11){ref-type="fig"}), resulting in aberrant apposition of nerve terminals and AChR clusters.

We did not observe such an aberrant apposition in our *Lrp4*^ECD/ECD^;*App*^−/−^ model or in *Lrp4*^ECD/ECD^;*Aplp2*^−/−^ mice. However, as in *Lrp4*^ECD/ECD^;*App*^−/−^, functional NMJ formation, as evidenced by greatly impaired postnatal survival ([Table 2](#tbl2){ref-type="table"}) and AChR clustering ([Figure 5](#fig5){ref-type="fig"}), is also significantly compromised in the *Lrp4*^ECD/ECD^;*Aplp2*^--/--^ double mutants. This would suggest that while APP and APLP2 are important for establishing trans-synaptic contact, LRP4 rather serves, through a hetero-oligomeric interaction with APP, MuSK and likely APLP2, to integrate agrin through cooperative binding into a spatially restricted signaling complex that focuses the molecular instructions required for AChR clustering at the surface of the muscle fiber.10.7554/eLife.00220.015Table 2.Survival analysis of *Lrp4*^ECD/ECD^;*Aplp2*^−/−^ double mutant pups**DOI:** [http://dx.doi.org/10.7554/eLife.00220.015](10.7554/eLife.00220.015)GenotypeExpectedObservedChi-square test*Lrp4*^+/ECD^;*Aplp2*^+/−^6882n.s.*Lrp4*^+/ECD^;*Aplp2*^−/−^6975n.s.*Lrp4*^ECD/ECD^;*Aplp2*^+/−^5851n.s.*Lrp4*^ECD/ECD^;*Aplp2*^−/−^5417[\*](#tblfn2){ref-type="table-fn"}[^6][^7][^8]

This oligomeric interaction of the LRP4 ECD may explain the residual function of the nonmembrane-associated soluble receptor in the LRP4 ECD mutants. While membrane anchoring firmly restricts LRP4 to the two-dimensional surface of the muscle fiber and thereby ensures its continued presence in the MuSK/agrin/APP/APLP2 signaling complex, the loss of the transmembrane segment can be partially compensated for by the combined interactions of APP, APLP2, MuSK and agrin with the LRP4 ECD. The reduced signal strength that results in impaired NMJ size and number can be explained by the inevitable reduction of LRP4 ectodomain at the NMJ and relative dilution of secreted ECD throughout the muscle surface and the interstitial space ([Figure 10](#fig10){ref-type="fig"}). This in turn is partially compensated for by the increased expression of LRP4 ECD in the heterozygous and homozygous mutants ([Figure 10E,F](#fig10){ref-type="fig"}).

We have further found that the non-neural Z0 as well as the neural Z8 and Z19 splice forms can bind to APP ([Figure 8D](#fig8){ref-type="fig"}). Interaction of Z0 (muscle) agrin, which cannot efficiently promote AChR clustering at physiological levels ([@bib35]), may have nevertheless physiological importance in this context by negatively regulating the recruitment of the MuSK activating, neural agrin isoforms outside of nerve contact sites, where their concentrations would be reduced. In doing so, muscle agrin would serve to potently suppress the formation of aberrant signaling complexes by blocking LRP4 and APP family proteins with the inactive form. This inhibition would be overcome by the higher concentrations of neural agrin at the nerve terminals.

On another note, we have previously shown that LRP4 can interact with several modulators of the Wnt pathways, that is Wise, Dkk, and Sost ([@bib13]; [@bib34]). These modulators bind to the homologous β-propeller domain in LRP5. It is intriguing to speculate that these interactions can also contribute to the modulation of NMJ development or function.

In summary, the findings we have reported here reveal new insights into the molecular mechanisms that govern the formation of the neuromuscular synapse and that are consistent with the recent findings from the Burden and Mei laboratories ([@bib62]; [@bib65]; [@bib68]). Furthermore, they raise interesting new questions about the interplay of agrin, MuSK, APP and LRP4 in the CNS where all these proteins are also expressed. There they might, in principle, work together in an analogous or similar manner to regulate synaptogenesis and promote neuronal survival. LRP4 belongs to an evolutionarily conserved class of ApoE receptors with essential functions in the regulation of neurotransmission at glutamatergic synapses ([@bib27]). We have recently shown that ApoE in an AD-associated, isoform-specific manner impairs ApoE receptor recycling at central synapses ([@bib8]) and that this impairs the ability of ApoE receptor-dependent signals to prevent β-amyloid induced synaptic suppression ([@bib14]). The findings we have reported here, together with those by Wang et al., who have proposed that perturbed APP synaptic adhesion activity may contribute to synaptic dysfunction and AD pathogenesis ([@bib58]), reaffirm the NMJ as a versatile and useful experimental model system on which the cell biology of ApoE, APP and ApoE receptor trafficking and its pathobiology at peripheral and central synapses can be investigated.

Materials and methods {#s4}
=====================

Recombinant rat agrin C-terminal fragment, Ala1153 Pro1959 (Pro1788-Ser1798del), with an N-terminal Met and 6xHis tag (Cat. \# 550-AG) was purchased from R&D Systems (Minneapolis, MN). *Lrp4*^ECD/ECD^ and *Lrp4*^−/−^ mice have been described previously ([@bib32]; [@bib34]). Rabbit polyclonal anti-syntaxin and rabbit polyclonal anti-synaptotagmin 2 were gifts from Dr Thomas Südhof, Stanford University School of Medicine, Palo Alto, CA, and used at 1:1000 dilution of immunofluorescence. Rabbit polyclonal anti-neurofilament (NF150) is from Chemicon, Temecula, CA, and was used at 1:1500 dilution. Rabbit polyclonal anti-LRP4 extracellular domain antibody was generated in the Kröger lab against the third and fourth beta-propeller domain of mouse LPR4 and was used at 1:100 dilution for immunofluorescence. Rabbit polyclonal anti-LRP4 antibody directed against the carboxyl-terminus of LRP4 was generated in the Herz lab and used for immunoblotting at 1:1000 dilution. Rabbit polyclonal anti-APP was generated in the Herz lab against the carboxyl-terminus of LRP4 and was used at 1:500 dilution for immunofluorescence.

Generation of mutant mice and animal husbandry {#s4-1}
----------------------------------------------

The generation of *App*^−/−^ ([@bib67]) and *Lrp4*^ECD/ECD^ ([@bib32]) mice has been reported. *Lrp4*^ΔICD/ΔICD^ mice were generated using the same targeting construct, except that sequences containing the LRP4 transmembrane segment followed by a Myc-epitope were introduced in place of the stop codon ([@bib33]). The *Lrp4*^ΔICD/ΔICD^ knockin mice were generated using a replacement vector based on the construct described for the LRP4 ECD mutant. The same long arm of homology, but lacking the introduced premature stop codon, was used. A cDNA insert expressing the transmembrane segment followed by a Myc epitope was cloned using an upstream Bst1107I site in the long arm and a BsrGI site in the bovine growth hormone 3′UTR. The oligonucleotide KI5 (5′-GTATACTGCTGATTTTGTTGGTGATCGCGGCTTTG-3′) was used as the 5′ primer and MEJ380 (5′-GTGTGTTGTACATCAGCTATTCAGATCCTCTTCTGAGATGAGTTTTTGTTCCTTGGATTTCCTGTGTCTGTATAGCATCAAAG-3′) was used as the 3′ primer to amplify the cDNA insert for the TM-Myc Epitope cassette.

*Lrp4* null mice were generated as described in [Figure 1](#fig1){ref-type="fig"} by replacing the first exon with a neomycin resistance cassette. The long arm of homology upstream of the first exon of *Lrp4* was generated by PCR amplification using the primers MEJ23 (5′-GCGGCCGCCAGGTCATGAAGTGAGTGCTGAGCCACTGGG-3′) and MEJ24 (5′-CCACCACCGCCTCATGGTGCTGCGGCCGCC-3′). The short arm of homology downstream of the first exon of *Lrp4* was generated by PCR amplification using the primers MEJ33 (5′-CTCGAGGAGCGGTCTGCAGATCCTGGCGATTCACGG-3′) and MEJ35 (5′-CTCGAGGGTTACAGACTCTGCAACTGCTCTACCTCATTG-3′). The long arm and short arm of homology were cloned into pJB1 using the NotI and XhoI restriction sites, respectively.

Animals were maintained on a mixed 129SvEv Bradley;C57BL/6J background by heterozygous intercrossing. Wild-type (WT) control mice were obtained from the same crosses. Animals were maintained on 12-hr light/12-hr dark cycles and fed a standard rodent chow diet (Diet 7001; Harlan Teklad, Madison, WI) and water ad libitum. No sexual dimorphism of phenotype was observed. All procedures were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern Medical Center at Dallas.

Production and purification of recombinant proteins {#s4-2}
---------------------------------------------------

A cDNA encoding the LRP4 ligand binding domain (LBD, aa 27--349, accession number CAM24075) was inserted downstream of the maltose-binding protein (MBP) coding sequence into pMAL-p4x (NEB). pMAL-p4x and pMAL-LRP4LBD-p4x constructs were expressed in *Escherichia coli* (BL21) to produce properly folded MBP and MBP-LRP4LBD fusion protein in the periplasm. Periplasmic extracts were subjected to amylose column (NEB, Ipswich, MA) to obtain affinity-purified MBP and MBP-LRP4LBD.

Fc fusion proteins were generated by fusing the extracellular domains of mouse LRP4 (residues 1--1650, LRP4-Fc), APP695 (residues 1--596, APP-Fc), or full length RAP (RAP-Fc) to the constant region of human IgG (Fc). Secreted fusion proteins were produced by transfecting HEK293A cells with pCDNA3.1-LRP4-Fc, pCDNA3.1-APP-Fc, or pCDNA3.1-RAP-Fc constructs using FuGENE 6 (Roche, Indianapolis, IN). Fc fusion proteins secreted into media were collected and purified on Protein A-Sepharose columns (Sigma, St. Louis, MO). APP-FLAG was generated by fusing 3xFLAG in place of Fc to the carboxyl-terminus of APP-695 (residues 1--596) in pCDNA3.1.

Protein interaction studies {#s4-3}
---------------------------

To investigate binding between LRP4 and APP, 100 ng of purified APP-Fc was incubated with Protein A-agarose beads (Sigma) in phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) for 4 hr at 4°C to generate Fc-agarose conjugates. The conjugates were then incubated with 100 ng of purified MBP or MBP-LRP4 LBD in PBS containing 0.1% BSA for 4 hr at 4°C. Protein coprecipitated with APP-Fc was detected by Western blotting with anti-MBP antibody (NEB), and the membrane was reprobed with anti-human IgG (Fc specific) antibody (Sigma) to determine the levels of APP-Fc.

To investigate binding between agrin and LRP4 or APP, 1.5 ml of LRP4-Fc, APP-Fc, or RAP-Fc conditioned medium was incubated with Protein A-agarose beads for 4 hr at 4°C to generate Fc-agarose conjugates. The conjugates were then incubated with 1 µg of neuronal agrin (R&D Systems) in Dulbecco's modified Eagle's medium (DMEM) containing 0.1% BSA for 4 hr at 4°C. Agrin coprecipitated with Fc fusion protein was detected by Western blotting with anti-agrin antibody (R&D Systems). The amount of Fc fusion protein present in the reaction was determined by reprobing the membrane with an anti-Fc antibody.

To investigate the role of agrin in LRP4--APP interaction, 100 ng of purified APP-Fc were conjugated to Protein A-agarose beads in PBS containing 0.1% BSA for 4 hr at 4°C. The conjugates were then incubated with 100 ng of purified MBP-LRP4LBD and 0--1000 ng of neuronal agrin in PBS containing 0.1% BSA for 4 hr at 4°C. The precipitates were then subjected to anti-MBP, anti-Agrin, or anti-Fc immunoblotting.

To investigate the differential interactions of Agrin isoforms with APP, we used constructs encoding the C-terminal 110 kDa fragments of agrin isoforms Z0, Z8 and Z19 containing N-terminal Flag tag and C-terminal Myc and 6xHis tags, respectively ([@bib6]; [@bib4]). These plasmids were generously provided by Dr Robert Burgess (Jackson Laboratory, Bar Harbor, ME). Agrin fragments were produced as secreted proteins in HEK293A cells grown in DMEM containing 0.1% BSA. 100 ng of purified APP-Fc or RAP-Fc was incubated with 300 µl of agrin containing supernatants overnight at 4°C followed by adsorption to Protein A Dynabeads (Invitrogen, Grand Island, NY) for 10 min at room temperature. After magnetic isolation, bound proteins and supernatants were analyzed by Western blotting using an anti-Myc antibody (9E10). Equal binding of the respective Fc proteins to the Dynabeads was detected by Western blotting using an anti-human IgG (Fc specific) antibody (Sigma, St. Louis, MO).

Co-immunoprecipitation of LRP4--APP--MuSK complex from muscle {#s4-4}
-------------------------------------------------------------

Hind limb muscle proteins in WT embryo (E14.5) were extracted in lysis buffer (PBS supplemented with 5 mM EDTA, 5 mM EGTA, 1% digitonin, and completed protease inhibitor tablet \[Roche\]). After centrifugation at 18,000×*g* for 5 min, the supernatant was incubated with 10 μl of an affinity purified anti-LRP4, anti-ApoER2, or anti-LRP1 antibody overnight at 4°C. Each antibody and bound proteins were absorbed to Protein A Dynabeads (Invitrogen) for 10 min at room temperature. After magnetic isolation, bound proteins and supernatants were analyzed by immunoblotting.

Cell aggregation assay {#s4-5}
----------------------

HEK293T cells were co-transfected for 48 hr with a 3:1 ratio of pDsRed:pCDNA3.1-LRP4 full-length constructs or of pEGFP:pCDNA3.1-APP full-length constructs to generate LRP4-expressing red-fluorescent and APP-expressing green-fluorescent cells, respectively. HEK293T cells transfected with pDsRed or pEGFP vector were used as control cells: red- or green-fluorescent cells. Cells were incubated with 0.05% Trypsin/0.53 mM EDTA in calcium- and magnesium-free Hank's balanced salt solution (HBSS) for 5 min followed by trituration, washed twice with HBSS and resuspended in aggregation buffer (0.1g glucose, 0.1 g BSA, 0.26 g HEPES, 13.75 mg CaCl~2~, and 10 mg DNase I in 100 ml HBSS). LRP4 and APP expression was determined from single cell suspensions by immunoblotting. LRP4-expressing red-fluorescent and APP-expressing green-fluorescent cells or red- and green-fluorescent cells were mixed and mutated at 37°C for 30 min in 16-mm wells precoated with 1% BSA. Aggregation was stopped by fixation with 2.5% glutaraldehyde. Cell suspensions were drop-plated and covered with coverslips. Fluorescent cell images were captured with a Zeiss 10x/0.30 NA dry objective on a Zeiss Axioplan 2 microscope. Aggregates of \>3000 µm^2^ in random fields were scored.

Immunofluorescence analysis {#s4-6}
---------------------------

Morphological analysis of the NMJ was carried out in both diaphragm and triangularis sterni muscles using procedures described previously ([@bib41]). Briefly, diaphragm (E14.5, E16.5, E18.5 or P12) or triangularis sterni (E18.5, P12 or 3-month-old) muscles were dissected out, fixed with 2% paraformaldehyde in 0.1 M phosphate buffer (pH 7.3) overnight at 4°C, washed thoroughly with PBS, and incubated with 0.1 M glycine in PBS for 30 min. Samples were incubated with Texas Red-conjugated α-bungarotoxin (2 nM, Molecular Probes) in antibody dilution buffer (0.01 M phosphate buffer, 500 mM NaCl, 3% BSA and 0.01% thimerosal) for 30 min at room temperature to label postsynaptic AChR, washed with PBS and incubated with rabbit polyclonal anti-neurofilament (1:1500; Chemicon, Billerica, MA) and rabbit polyclonal anti-synaptotagmin 2 (1:1000, a generous gift from Dr Thomas Südhof, Stanford University School of Medicine, Palo Alto, CA) antibodies diluted in antibody dilution buffer overnight at 4°C to stain presynaptic motor axons. For sections, samples were incubated in antibodies against LRP4 (rabbit polyclonal, 1:100) or APP (rabbit polyclonal, 1:500) overnight at room temperature. After washing three times with 0.5% Triton X-100 in PBS, samples were incubated with FITC-conjugated anti-rabbit IgG overnight at 4°C, washed in PBS, and mounted in Vectashield mounting medium. Fluorescent images were captured using a Zeiss LSM 510 confocal microscope. Quantitative measurements of AChR cluster number and size were made using NIH ImageJ software. For the analysis of AChR cluster number, Texas Red-labeled AChR clusters on the same right ventral region of each diaphragm were counted. For the analysis of AChR size, images acquired at high magnification were used.

To determine LRP4 distribution, hindlimb muscles from E14.5, E16.5 and E18.5 embryos were transversely sectioned (20 μm). Sections were incubated with 2 nM of Texas Red-conjugated α-bungarotoxin for 30 min at room temperature to label postsynaptic AChR. Then, sections were incubated with rabbit polyclonal antibody against LRP4 extracellular domain (1:100) overnight at 4°C. After washing with 0.1% Triton X-100 in PBS, the samples were incubated with fluorescein isothiocyanate-conjugated anti-rabbit IgG for 2 hr at room temperature, washed with PBS and mounted in Vectashield mounting medium. Images were acquired under an upright fluorescence microscope (Olympus BX51) using a Hamamatsu ORCA-285 camera, and fluorescence intensity (mean gray value) was measured using NIH ImageJ.

3D reconstruction of confocal images {#s4-7}
------------------------------------

Images were captured using a Zeiss LSM 510 META confocal microscope with a Zeiss 40x/1.3 NA oil immersion objective. Excitation wavelengths used for the red and green channels were 543 nm (HeNe1 Laser) and 488 nm (Argon Laser), respectively. Z-stacks were acquired at an optical slice interval of 0.6 μm. The Reuse feature from the Zeiss LSM acquisition software allowed capturing of all images at the same laser power, detector gain and amplifier offset for all specimens. 3D reconstruction of the Z-stack images was done using Imaris software (Bitplane Inc, MN). Initial image analysis included applying the background subtraction algorithm in Imaris. The intensity for the green and red channels was adjusted in Blend mode during volume rendering and an Iso Surface model was created for the background-subtracted images.

Electron microscopy {#s4-8}
-------------------

Ultrastructural analysis of the NMJ was carried out as previously described ([@bib70]; [@bib7]). Deeply anesthetized animals were fixed via cardiac perfusion with a mixture of 1% glutaraldehyde and 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Lumbrical muscles were dissected and post-fixed in the same solution overnight at 4°C. Tissues were then rinsed with the 0.1 M phosphate buffer, trimmed to small pieces and post-fixed with 1% osmium tetroxide for 3 hr on ice. Tissues were then dehydrated in a graded series of ethanol, infiltrated and polymerized in Epon 812 (Polysciences, Warrington, PA). Epon blocks were cut at 1 μm and stained with toluidine blue for light microscopic observation. Ultrathin (70 nm) sections were mounted on Formvar-coated grids and stained with uranyl acetate and lead citrate. Electron micrographs were acquired using a Tecnai (Netherlands) electron microscope operated at 120 kV.

AChR clustering assay {#s4-9}
---------------------

Mouse C2C12 cells maintained as undifferentiated myoblasts in DMEM supplemented with 20% fetal bovine serum and 0.5% chick embryo extract were seeded on 8-well plastic chamber slides (Nalge Nunc International, Rochester, NY) and grown to ∼90% confluence. Myoblasts were fused into myotubes in differentiation medium (DMEM supplemented with 2% horse serum) for 3 days. Myotubes were incubated with 300 μl differentiation medium containing 3 μl Protein A-agarose beads (50% slurry in PBS containing 0.1% BSA) conjugated without or with saturating amounts of APP-Fc or RAP-Fc for 24 hr in the absence or presence of 0.1 ng/ml agrin. At the end of the incubation, myotubes were fixed with 1% paraformaldehyde in 0.1 M phosphate buffer for 30 min, washed with PBS and incubated with 2 nM of Texas-Red conjugated α-bungarotoxin (Molecular Probes, Grand Island, NY) for 30 min to label AChRs. Myotubes were then washed with PBS and mounted in Vectashield mounting medium. For each sample, 50 fluorescent images were randomly captured using a Hamamatsu ORCA-285 camera under 400× magnification. A cluster with a length \>2 μm was defined as a patch of AChRs. All the myotubes that had AChR clusters in the fields were analyzed blindly, and the size and number of AChR clusters/200 µm myotube length were measured using NIH ImageJ software and normalized to control levels.

Primary myotube culture {#s4-10}
-----------------------

Muscles were quickly removed from the limbs of WT, *Lrp4*^−/−^, and *Musk*^−/−^ embryos (E18.5) in Hanks' Balanced Salt Solution (Invitrogen). Muscles were minced into small pieces before enzymatic digestion for 45 min at 37°C in HBSS supplemented with 2 mg/ml of Type II collagenase (Worthington) and 0.4 mg/ml of DNAse l (Worthington, Lakewood, NJ). Dissociated muscle cells were collected by centrifugation at 2000×*g* for 5 min, resuspended in culture medium (DMEM supplemented with 10% horse serum, 5% fetal calf serum and 1% chick embryo extracts), and filtered through a Cell Strainer with diameter of 100 µm (BD Falcon, San Jose, CA). Cells were then seeded on a 100-mm culture dish and incubated in a 37°C, 5% CO~2~ incubator for 2 hr in order to attach and remove fibroblasts. Suspended myoblasts were collected by centrifugation at 2000×*g* for 5 min and seeded on 8-well plastic chamber slides (Fisher, Pittsburgh, PA). After growing cells in the culture medium until approximately 90% confluence, the culture medium was replaced with differentiation medium (DMEM supplemented with 2% horse serum), and this medium was changed every day for 3 days to fuse myoblasts into myotubes for the AChR clustering assay as described.

MuSK phosphorylation assay {#s4-11}
--------------------------

Differentiated myotubes were incubated with indicated concentrations of agrin, APP-Fc, or RAP-Fc for 30 min at 37°C. The myotubes were rinsed once on ice with PBS containing 1 mM sodium orthovanadate and 50 mM sodium fluoride and extracted in lysis buffer (30 mM triethanolamine, 1% NP-40, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 50 mM sodium fluoride, 2 mM sodium orthovanadate, 1 mM sodium tetrathionate, 1 mM N-ethylmaleimide, 10 µM Pepstatin, 0.5 mg/ml Pefabloc, and complete protease inhibitor tablet \[Roche\]). Lysates were centrifuged at 18,000×*g* for 5 min and the supernatant was used as total myotube extracts. To immunoprecipitate MuSK, the extracts were incubated overnight at 4°C with anti-MuSK antibody (Abcam, Cambridge, MA) followed by precipitation of the antibody with Protein A/G PLUS-Agarose (Santa Cruz, Dallas, TX). Precipitated MuSK was separated by SDS-PAGE and the phosphorylation (activation) status of MuSK was determined by Western blotting using anti-phosphotyrosine antibody 4 G10 Platinum (Millipore, Billerica, MA). Molarities are stated for monomers.

Statistical analyses {#s4-12}
--------------------

Data are presented as mean ± standard error of the mean (SEM). Statistical analyses of differences between or among control, mutant and treatment groups were carried out using Student's *t* test or one-way analysis of variance (ANOVA). Post hoc test was carried out by using Tukey analyses when a significant F-value was obtained in ANOVA. A p value of \<0.05 was considered to be significant.

Funding Information
===================

This paper was supported by the following grants:

-   National Institutes of Health HL20948, HL63762, NS055028 to Weichun Lin, Joachim Herz.

-   American Health Assistance Foundation to Joachim Herz.

-   Lupe Murchison Foundation to Joachim Herz.

-   Consortium for Frontotemporal Dementia Research to Joachim Herz.

-   Deutsche Forschungsgemeinschaft SFB780 to Joachim Herz.

-   Alexander von Humboldt Stiftung to Joachim Herz.

-   Brightfocus Foundation to Joachim Herz.

-   Alzheimer's Disease Center to Yun Liu.

-   Cain Foundation in Medical Research to Weichun Lin.

We are indebted to Gary Philips for critical reading of the manuscript, and to Mike Brown and Joe Goldstein for helpful suggestions. We thank Robert Burgess for agrin constructs, Wen-Ling Niu, Huichuan Reyna, Priscilla Rodriguez, Rebekah Hewitt, Vicki Kerr, and Isaac Rocha for excellent technical assistance, and Nancy Heard for invaluable help with artwork.

Additional information
======================

The authors declare that no competing interests exist.

HYC, Conception and design, Acquisition of data, Analysis and interpretation of data.

YL, Conception and design, Acquisition of data, Analysis and interpretation of data.

CT, Acquisition of data.

EBJ, Acquisition of data.

YS, Acquisition of data, Analysis and interpretation of data.

AK, Generated the unpublished antibody against the LRP4 extracellular domain.

SK, Generated the unpublished antibody against the LRP4 extracellular domain.

REH, Performed all transgene manipulations in vivo.

WL, Conception and design, Analysis and interpretation of data, Drafting or revising the article.

JH, Conception and design, Analysis and interpretation of data, Drafting or revising the article.

Animal experimentation: The animal experiments described in this paper were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at UT Southwestern where the experiments were exclusively conducted. The animal assurance number is A3472-01. All experiments were conducted along the guidelines described in "The Guide for the Care and Use of Laboratory Animals": Eighth Edition; Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council; ISBN: 0-309-15401-4, 248 pages, 6 x 9, (2010). This PDF is available from the National Academies Press at: <http://www.nap.edu/catalog/12910.html>.

10.7554/eLife.00220.016

Decision letter

Buckingham

Margaret

Reviewing editor

Institut Pasteur

,

France

eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elife.elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for choosing to send your work entitled "APP Interacts with LRP4 and Agrin to Coordinate the Development of the Neuromuscular Junction in Mice" for consideration at *eLife*. Your article has been evaluated by a Senior editor, a Reviewing editor, and 3 reviewers. The Reviewing editor has assembled the following comments based on the reviewers\' reports.

This is an interesting manuscript that reports the novel finding that APP participates in the signaling that underlies the formation of the neuromuscular junction (NMJ), together with agrin, LRP4 and MuSK. Although the role of APP in this context was suggested in several previous publications, this is the first study that combines molecular genetics, cell biology and biochemical methods to delineate its involvement in agrin-LRP4-MuSK signaling. A number of points need to be addressed by the authors to substantiate the model they propose.

1\) The authors propose that APP participates in the anchoring of the LRP4 extra-cellular domain at the NMJ. However, although the APP/LRP4 interaction is shown and although the deletion of APP worsens the LRP4 ECD phenotype, no direct evidence supports this hypothesis. The demonstration would be more convincing if muscle immunostaining showed the localization of LRP4 ECD at the NMJ in the presence and absence of APP. One would expect LRP4 ECD accumulation to decrease in the absence of APP. Alternatively LRP4ECD-GFP fusions could be expressed in WT and APP^-/-^ muscles. LRP4 ECD retention at the membrane, and/or colocalization with MuSK, could also be evaluated in cultured myotubes expressing APP, or not.

It would also be informative to know more about the expression patterns of APP and LRP4. A previous study suggested that the expression of APP in muscles starts at E16 and is concentrated at NMJs progressively ([@bib1], MCN 15:355). It is unclear if APP and LRP4 are expressed in a spatially and temporally correlated manner. The authors should provide a developmental expression profile of these two proteins in both motoneurons and muscles.

2\) In vitro studies seem to suggest that APP is sufficient to induce AChR clusters in cultured muscles. However, there was no discernible phenotype of the APP^-/-^ mutant, until the transmembrane domain of LRP4 was truncated. Because APP could bind both muscle and neuronal agrin, an interesting question is if APP acts by aggregating agrin. The conclusion in the text and in the model ([Figure 10](#fig10){ref-type="fig"}) that APP-LRP4 interaction in the absence of agrin can activate MuSK to promote AChR clustering is not supported by the data shown. C2C12 cells express muscle agrin, which binds to APP as shown in [Figure 9](#fig9){ref-type="fig"}. APP\'s effect could be studied in agrin^-/-^ or KD muscle fibers. Alternatively, if APP overexpression could rescue the agrin null phenotypes in vivo that would be ever better. The authors should also check ectopic AChR cluster formation induced by agrin under LRP4^ECD/ECD^ and LRP4^ECD/ECD^ APP^-/-^ conditions; again, this could be done in isolated muscle fibers.

3\) The authors propose that APP could constitute the factor through which neuromuscular contacts initially form independently of agrin. This hypothesis is very interesting but requires additional proof, such as showing that, in the absence of agrin, APP is required for these initial contacts to form. It would be time consuming to cross APP^-/-^ and agrin^-/-^ mice, but the authors could already evaluate the implication of APP and APLP2 in the initial steps of neuromuscular junction formation by evaluating the requirement of these proteins for the prepatterning of AChR clusters that precedes nerve-muscle contact, i.e., by analyzing muscle prepatterning in APP^-/-^ and APLP2^-/-^ mice.

4\) The demonstration of the interaction between APP and LRP4 is strong and convincing. In light of the recent results published by Steve Burden and colleagues showing that LRP4 constitutes the attraction signal for motoneurones, it is tempting to speculate from the present data that APP could constitute the neuronal ligand of LRP4. Primary motoneuron cultures from APP^-/-^ mice could be cocultured with LRP4 beads to challenge this hypothesis.

5\) In one set of binding assays, the LDB fragment was used. There was no data to show that this domain was required for fl LRP4 interaction with APP. This could be tested in experiments described in [Figure 7](#fig7){ref-type="fig"}. Furthermore there were no data that showed the LRP4-APP interaction was necessary for NMJ formation or maturation. Ideally it should be shown in vivo that LRP4 without the LBD cannot rescue, but LRP4 wt can rescue the null phenotypes. At the very least, in vitro studies should be performed to see if APP-induced AChR clustering and MuSK activation requires the LBD. Moreover, description of this domain should be included in the Results rather than within the Methods. This domain, aa 27--349, has been shown to interact with MuSK. Perhaps the authors can comment in the Discussion on whether this domain interacts with WISE, DKK, and SOST?

*Other points of presentation that need attention*:

a\) The conclusion that "membrane anchoring of the receptor is required to maintain the level of signal strength necessary for postnatal maturation of the synapse" seems to be a misinterpretation. Many "maturation" events at ECD/ECD NMJs were apparently normal, including synapse elimination, subunit switch, etc.

b\) There is some concern regarding the conclusion that "the failure of RAP-Fc to induce AChR clustering suggests that LRP4 dimerization alone is not sufficient, but that possibly the formation of an extracellular scaffold". No data to show that RAP-Fc binds to LRP4 is presented in this paper. It binds to ApoE, but this does not suggest that it also binds LRP4. If it does, where in LRP4 does it bind? The LBD?

c\) Based on the fluorescent images presented in [Figure 6](#fig6){ref-type="fig"}, the impairment of postsynaptic differentiation, as illustrated by AChR clusters, in APP/LRP4^ECD^ double mutant is subtle. A quantitative analysis is required to show if the double mutant significantly affects postsynaptic differentiation.
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Author response

*The authors propose that APP participates in the anchoring of the LRP4 extra-cellular domain at the NMJ. However, although the APP/LRP4 interaction is shown and although the deletion of APP worsens the LRP4 ECD phenotype, no direct evidence supports this hypothesis. The demonstration would be more convincing if muscle immunostaining showed the localization of LRP4 ECD at the NMJ in the presence and absence of APP. One would expect LRP4 ECD accumulation to decrease in the absence of APP. Alternatively LRP4ECD-GFP fusions could be expressed in WT and APP*^*-/-*^ *muscles. LRP4 ECD retention at the membrane, and/or colocalization with MuSK, could also be evaluated in cultured myotubes expressing APP, or not*.

*It would also be informative to know more about the expression patterns of APP and LRP4. A previous study suggested that the expression of APP in muscles starts at E16 and is concentrated at NMJs progressively (*[@bib1]*, MCN 15:355). It is unclear if APP and LRP4 are expressed in a spatially and temporally correlated manner. The authors should provide a developmental expression profile of these two proteins in both motoneurons and muscles*.

We thank the reviewers for this excellent suggestion. We have carried out immunostaining using antibodies against the LRP4 ectodomain. As expected and envisioned by the reviewer, we found that anti-LRP4 immunostaining was more diffuse in LRP4^ECD/ECD^ and in APP/APLP2 double knockout muscle compared to WT muscle ([Figure 10](#fig10){ref-type="fig"}). These results impressively show that LRP4 and APP family members are co-expressed and stabilize each other at the NMJ, as also demonstrated by [Figure 8A](#fig8){ref-type="fig"}.

We have investigated the localization of LRP4 and APP during NMJ synaptogenesis at E14.5, E16.5 and E18.5, using anti-LRP4 and anti-APP antibodies. We found that both LRP4 and APP were localized at the NMJ at E18.5. However, at E14.5 or E16.5 the staining was diffusely distributed across the muscle surface. These requested data are now included in the manuscript as part of [Figure 10](#fig10){ref-type="fig"}. Additionally, we have carried out immunostaining on embryonic spinal cord sections (E14.5, E16.5 and E18.5), using anti-LRP4 or anti APP antibodies. However, we were unable to detect specific staining for both antibodies in the spinal cord at all three stages.

*2) In vitro studies seem to suggest that APP is sufficient to induce AChR clusters in cultured muscles. However, there was no discernible phenotype of the APP*^*-/-*^ *mutant, until the transmembrane domain of LRP4 was truncated. Because APP could bind both muscle and neuronal agrin, an interesting question is if APP acts by aggregating agrin. The conclusion in the text and in the model (*[*Figure 10*](#fig10){ref-type="fig"}*) that APP-LRP4 interaction in the absence of agrin can activate MuSK to promote AChR clustering is not supported by the data shown. C2C12 cells express muscle agrin, which binds to APP as shown in* [*Figure 9*](#fig9){ref-type="fig"}*. APP\'s effect could be studied in agrin*^*-/-*^ *or KD muscle fibers. Alternatively, if APP overexpression could rescue the agrin null phenotypes* in vivo *that would be ever better. The authors should also check ectopic AChR cluster formation induced by agrin under LRP4*^*ECD/ECD*^ *and LRP4*^*ECD/ECD*^ *APP*^*-/-*^ *conditions; again, this could be done in isolated muscle fibers*.

We agree with the reviewer that these would be informative experiments. For the time being, they have not given us conclusive in vitro results. We will need to pursue this point further by generating agrin^-/-^;APP^-/-^;APLP2^-/-^ triple mutant mice. This is a challenge magnified by the low viability of the compound mutants. We have toned down our statements in the text and the discussion accordingly.

*3) The authors propose that APP could constitute the factor through which neuromuscular contacts initially form independently of agrin. This hypothesis is very interesting but requires additional proof, such as showing that, in the absence of agrin, APP is required for these initial contacts to form. It would be time consuming to cross APP*^*-/-*^ *and agrin*^*-/-*^ *mice, but the authors could already evaluate the implication of APP and APLP2 in the initial steps of neuromuscular junction formation by evaluating the requirement of these proteins for the prepatterning of AChR clusters that precedes nerve-muscle contact, i.e., by analyzing muscle prepatterning in APP*^*-/-*^ *and APLP2*^*-/-*^ *mice*.

We thank the reviewers for this excellent point. We have initiated the experiment by breeding agrin mutant mice with APP and APLP2 mutant mice. Because of the redundancy of APP and APLP2, we will need to study agrin/APP/APLP2 triple mutant mice to properly evaluate the effect. Due to the time required for this extensive breeding we have not obtained the triple mutant mice. However, we have evaluated the implication of APP and APLP2 in the prepatterning of AChR clusters in E14.5 APP/APLP2 double mutant muscle. As shown in [Figure 9](#fig9){ref-type="fig"}, AChRs are clustered along the central region of E14.5 APP/APLP2 double mutant muscle. Intriguingly, individual AChR clusters appear less robust compared with those in the wild type, APP null or APLP2 null muscles. These results demonstrate that prepatterned AChR clustering can occur in the absence of APP and APLP2.

*4) The demonstration of the interaction between APP and LRP4 is strong and convincing. In light of the recent results published by Steve Burden and colleagues showing that LRP4 constitutes the attraction signal for motoneurones, it is tempting to speculate from the present data that APP could constitute the neuronal ligand of LRP4. Primary motoneuron cultures from APP*^*-/-*^ *mice could be cocultured with LRP4 beads to challenge this hypothesis*.

We thank reviewers for this insightful comment. It is interesting that the results published by Steven Burdenʼs group (Yumoto, et al., Nature 2012) and Mei Linʼs group (Wu, et al., Neuron 2012) have shown that LRP4 expressed in non-muscle cells can induce presynaptic differentiation by aggregating presynaptic markers such as synapsin and SV2. Furthermore, studies from Lin Meiʼs group (Wu et al., Neuron, 2012) have shown that muscle specific deletion of LRP4 impairs both pre and postsynaptic development of the NMJ and that LRP4 in motor neurons is necessary for presynaptic differentiation of motor axons. It is tempting to speculate that APP, APLP2, or both, may serve as the neuronal ligand for LRP4 in inducing presynaptic differentiation. However, in vivo evidence indicates that APP/APLP2 is unlikely to be the major player in inducing presynaptic differentiation, because presynaptic differentiation is only mildly affected in neuronal specific deletion of APP/APLP2 (Wang et al., J Neuroscience 2009).

*5) In one set of binding assays, the LDB fragment was used. There was no data to show that this domain was required for fl LRP4 interaction with APP. This could be tested in experiments described in* [*Figure 7*](#fig7){ref-type="fig"}*. Furthermore there were no data showed that the LRP4-APP interaction was necessary for NMJ formation or maturation. Ideally it should be shown* in vivo *that LRP4 without the LBD cannot rescue, but LRP4 wt can rescue the null phenotypes. At the very least,* in vitro *studies should be performed to see if APP- induced AChR clustering and MuSK activation requires the LBD. Moreover, description of this domain should be included in the Results rather than within the Methods. This domain, aa 27-349, has been shown to interact with MuSK. Perhaps the authors can comment in the Discussion on whether this domain interacts with WISE, DKK, and SOST*?

We show that the LBD fragment is sufficient for interaction with APP. We therefore did not test specifically whether the β-propeller portion of LRP4 also contributes to the interaction or not. Although this would ultimately provide additional structural detail to the demonstrated interaction between LRP4 and APP, it would not change the biological significance of the present study or the conclusions. We agree that in a future study one might address whether the interaction of LRP4, APP, agrin and MuSK can also be regulated by the various signal modulators (Wise, Dkk, Sost) that we have previously shown to bind to LRP4. Incidentally, Wise, Dkk and Sost all interact with the homologous β-propeller domain in LRP5/6. We ask for the reviewers' and the editors' understanding that to conclusively address this question would be more suitable for a full-fledged study in its own right.

Other points of presentation that need attention:

*a) The conclusion that "membrane anchoring of the receptor is required to maintain the level of signal strength necessary for postnatal maturation of the synapse" seems to be a misinterpretation. Many "maturation" events at ECD/ECD NMJs were apparently normal, including synapse elimination, subunit switch, etc*.

We thank the reviewers for these clarifying comments. Synapse elimination and subunit switch proceed normally at the NMJ in the LRP4ECD/ECD mice and we have revised the manuscript accordingly.

*b) There is some concern regarding the conclusion that "the failure of RAP- Fc to induce AChR clustering suggests that LRP4 dimerization alone is not sufficient, but that possibly the formation of an extracellular scaffold". No data to show that RAP- Fc binds to LRP4 is presented in this paper. It binds to ApoE, but this does not suggest that it also binds LRP4. If it does, where in LRP4 does it bind? The LBD*?

We apologize for omitting the appropriate citation. This is now included ([@bib46]). Note: RAP does not bind to ApoE. It universally binds to the ligand binding domains of ApoE receptors, i.e. the LDL receptor gene family. The structural basis for this has been nicely worked out by Steve Blacklow and colleagues (Structure of an LDLR-RAP Complex Reveals a General Mode for Ligand Recognition by Lipoprotein Receptors. Fisher C, Beglova N, Blacklow SC. Mol Cell. 2006 Apr 21;22(2):277-83). This reference has now also been cited.

*c) Based on the fluorescent images presented in* [*Figure 6*](#fig6){ref-type="fig"}*, the impairment of postsynaptic differentiation, as illustrated by AChR clusters, in APP/LRP4 ECD double mutant is subtle. A quantitative analysis is required to show if the double mutant significantly affects postsynaptic differentiation*.

These data have been quantified and statistically analyzed. They are now shown in [Figure 4](#fig4){ref-type="fig"} panel C.

[^1]: These authors contributed equally to this work.

[^2]: Department of Operative Dentistry and Periodontology, University School and Dental Hospital, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.

[^3]: *Note:* 41% (20/49) of *Lrp4*^ECD/ECD^;*App*^+/−^ died within five months of age; 13% (6/45) of *Lrp4*^+/ECD^;*App*^−/−^ mice died within five months of age.

[^4]: n.s., not significant.

[^5]: Significant at p\<0.01. Survival was scored at weaning (P25). The 'Expected' column states the number of offspring of the indicated genotype according to the rules of Mendelian inheritance. The 'Observed' column states the number of offspring found to have the indicated genotype. Chi-square analysis of these data indicates whether the observed number significantly deviates from the expected number or not.

[^6]: n.s., not significant.

[^7]: Significant at p\<0.01.

[^8]: Pups were genotyped at weaning (∼25 days of age) to determine postnatal survival rates.
